You have free access to this content

Cancer

Cover image for Vol. 119 Issue 20

15 October 2013

Volume 119, Issue 20

Pages 3581–3738

  1. Issue information

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
      Issue information (pages i–viii)

      Version of Record online: 7 DEC 2015 | DOI: 10.1002/cncr.29821

  2. CancerScope

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
      HPV infections among teen girls on the decline (page 3583)

      Carrie Printz

      Version of Record online: 4 OCT 2013 | DOI: 10.1002/cncr.28391

  3. Commentaries

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
      Addressing overtreatment in breast cancer: The doctors' dilemma (pages 3584–3588)

      Steven J. Katz and Monica Morrow

      Version of Record online: 2 AUG 2013 | DOI: 10.1002/cncr.28260

      • image

      Patients with favorable prognosis of breast cancer are vulnerable to overtreatment because the absolute net benefit of different treatments may be small and difficult to quantify in individual cases. Advances in personalized treatment hold the promise of increasing the certainty of the treatment benefit of different treatments in individual patients, but insufficient attention has been paid to the challenges to treatment decision-making.

    2. You have free access to this content
      Dynamic prognostication using conditional survival estimates (pages 3589–3592)

      Emily C. Zabor, Mithat Gonen, Paul B. Chapman and Katherine S. Panageas

      Version of Record online: 1 AUG 2013 | DOI: 10.1002/cncr.28273

      • image

      Conditional survival estimates provide dynamic prognostication using the information that a given patient has survived some time after baseline, and are obtained through the baseline Kaplan-Meier estimates. The routine use of conditional survival estimates is strongly recommended by the authors.

  4. Editorial

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
      Racial differences in chronic lymphocytic leukemia: Digging deeper (pages 3593–3595)

      Christopher R. Flowers and Barbara Pro

      Version of Record online: 8 JUL 2013 | DOI: 10.1002/cncr.28233

      African American patients with untreated chronic lymphocytic leukemia receiving care at The University of Texas MD Anderson Cancer Center and Duke University Medical Center more commonly presented with poor-risk biological features and had worse survival. These results provide additional clinical details to understand the nature of racial disparities in patients with chronic lymphocytic leukemia.

  5. Original Articles

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    7. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study (pages 3596–3603)

      Anne Marie McCarthy, Mirar Bristol, Tracey Fredricks, Lache Wilkins, Irene Roelfsema, Kaijun Liao, Judy A. Shea, Peter Groeneveld, Susan M. Domchek and Katrina Armstrong

      Version of Record online: 16 JUL 2013 | DOI: 10.1002/cncr.28268

      • image

      A population-based survey of patients with breast cancer suggests that although BRCA1/2 testing recommendations appear to be appropriately correlated with mutation risk, a significant percentage of patients with breast cancer who meet the criteria for BRCA1/2 testing may not receive recommendations for such testing from their providers.

    2. Gastrointestinal Disease
      You have free access to this content
      Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer (pages 3604–3609)

      Zhe Jin, Zhenfu Zhao, Yulan Cheng, Ming Dong, Xiaojing Zhang, Liang Wang, Xinmin Fan, Xianling Feng, Yuriko Mori and Stephen J. Meltzer

      Version of Record online: 24 JUL 2013 | DOI: 10.1002/cncr.28276

      • image
      • image

      Using real-time, quantitative, methylation-specific polymerase chain reaction, the authors examined promoter hypermethylation of endoglin (ENG) in 260 endoscopic esophageal biopsy specimens of differing histologies. Results demonstrated that hypermethylation of ENG is a common, tissue-specific event in patients with esophageal squamous cell carcinoma and exhibits a field defect in normal mucosa with potential biomarker implications for the early detection of this disease.

    3. Genitourinary Disease
      You have free access to this content
      Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): Important lessons for future trials (pages 3610–3618)

      Michael T. Schweizer, Peng Huang, Michael W. Kattan, Adam S. Kibel, Ronald de Wit, Cora N. Sternberg, Jonathan I. Epstein and Mario A. Eisenberger

      Version of Record online: 13 AUG 2013 | DOI: 10.1002/cncr.28270

      • image
      • image
      • image
      • image
      • image

      The role of adjuvant systemic therapy after radical prostatectomy in patients with prostate cancer remains unclear. Trials in these patients are difficult for a multitude of reasons.

    4. You have free access to this content
      Determinants of the combined use of external beam radiotherapy and brachytherapy for low-risk, clinically localized prostate cancer (pages 3619–3628)

      Ruben G. W. Quek, Viraj A. Master, Kevin C. Ward, Chun Chieh Lin, Katherine S. Virgo, Kenneth M. Portier and Joseph Lipscomb

      Version of Record online: 31 JUL 2013 | DOI: 10.1002/cncr.28258

      • image
      • image
      • image

      Geographic and sociodemographic factors are significantly associated with receipt of guideline-discordant radiotherapy for low-risk, clinically localized prostate cancer. Which radiation oncologist a patient consults is important in determining whether they receive combined radiotherapy.

    5. You have free access to this content
      Quality of prostate cancer care among rural men in the Veterans Health Administration (pages 3629–3635)

      Ted A. Skolarus, Stephanie Chan, Jeremy B. Shelton, Anna Liza Antonio, Anne E. Sales, Jennifer L. Malin and Christopher S. Saigal

      Version of Record online: 30 JUL 2013 | DOI: 10.1002/cncr.28275

      Rural patients with prostate cancer have less access to comprehensive oncology resources, although they receive a similar quality of care, compared with their urban counterparts in the Veterans Health Administration integrated care delivery system. A better understanding of the degree to which facility factors contribute to the quality of cancer care may assist other organizations involved in rural health care delivery.

    6. You have free access to this content
      The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: Results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance) (pages 3636–3643)

      Rahul Aggarwal, Susan Halabi, William Kevin Kelly, Daniel George, John F. Mahoney, Frederick Millard, Walter M. Stadler, Michael J. Morris, Philip Kantoff, J. Paul Monk, Michael Carducci, Eric J. Small and for the Alliance for Clinical Trials in Oncology

      Version of Record online: 31 JUL 2013 | DOI: 10.1002/cncr.28285

      • image
      • image

      A retrospective analysis of patients with metastatic, castrate-resistant prostate cancer who receive docetaxel-based chemotherapy on a randomized phase 3 clinical trial (CALGB 90401) does not provide evidence of an adverse impact of prior androgen synthesis inhibition with ketoconazole on subsequent clinical outcomes, contrary to preliminary evidence of cross-resistance between these modalities of therapy. The study results may have implications for the sequencing of novel androgen synthesis inhibitors and taxane-based chemotherapy, highlighting the need for prospective, randomized clinical trials to define the optimal sequence of therapy for metastatic, castration-resistant prostate cancer.

    7. Gynecologic Oncology
      You have free access to this content
      Racial disparities in cervical cancer survival over time (pages 3644–3652)

      J. Alejandro Rauh-Hain, Joel T. Clemmer, Leslie S. Bradford, Rachel M. Clark, Whitfield B. Growdon, Annekathryn Goodman, David M. Boruta II, John O. Schorge and Marcela G. del Carmen

      Version of Record online: 31 JUL 2013 | DOI: 10.1002/cncr.28261

      • image

      After adjusting for race, SEER registry, marital status, stage, age, treatment, grade, and histology, there was a significant difference in cervical cancer–specific mortality between 1985 to 1989 and 1990 to 1994, but not after 1995.

    8. You have free access to this content
      Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer (pages 3653–3661)

      Jason C. Barnett, Angeles Alvarez Secord, David E. Cohn, Charles A. Leath III, Evan R. Myers and Laura J. Havrilesky

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28283

      • image
      • image
      • image
      • image

      The addition of bevacizumab to standard chemotherapy for the primary treatment of ovarian cancer is not cost effective by common willingness-to-pay thresholds. However, when bevacizumab is incorporated into treatment only for patients with a poor prognosis or for those with a positive predictive genetic test, it may be a more cost-conscious approach.

    9. Hematologic Malignancies
      You have free access to this content
      Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project (pages 3662–3671)

      Andrew M. Evens, Ann Vanderplas, Ann S. LaCasce, Allison L. Crosby, Auayporn P. Nademanee, Mark S. Kaminski, Gregory A. Abel, Michael Millenson, Myron S. Czuczman, Maria A. Rodriguez, Joyce Niland, Andrew D. Zelenetz, Leo I. Gordon and Jonathan W. Friedberg

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28243

      • image
      • image
      • image

      We identified several critical prognostic factors that predicted survival within and across autologous stem cell transplantation (autoSCT) and allogeneic SCT (alloSCT) cohorts and a prognostic survival model was created for patients with relapsed/refractory follicular lymphoma in the post-rituximab era. Additionally, overall survival appeared improved for autoSCT versus alloSCT including on multivariate analysis and with propensity scoring/matching.

    10. You have free access to this content
      Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database (pages 3672–3679)

      Jorge J. Castillo, Eric S. Winer and Adam J. Olszewski

      Version of Record online: 30 JUL 2013 | DOI: 10.1002/cncr.28264

      • image
      • image
      • image
      • image

      In this study, the outcome of patients with Burkitt lymphoma was evaluated from the SEER (Surveillance, Epidemiology, and End Results) database, from 1998 to 2009. In the last decade, there has been an improved survival in patients younger than 60 years; however, the survival of older patients and black patients has not improved. Population-based prognostic factors for survival were identified, and a risk-stratification model was constructed.

    11. You have free access to this content
      Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma (pages 3680–3686)

      Guillemette Fouquet, Stéphanie Tardy, Hélène Demarquette, Sarah Bonnet, Julie Gay, Houria Debarri, Charles Herbaux, Stéphanie Guidez, Jessica Michel, Aurore Perrot, Caroline Serrier, Darko Miljkovic, Hervé Avet Loiseau, Thierry Facon, Cyrille Hulin and Xavier Leleu

      Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28274

      • image

      The objective of the current study was to determine the efficacy and safety profile of long-term exposure (≥ 2 years) to the combination of lenalidomide and dexamethasone in 50 patients with recurrent/refractory multiple myeloma (RRMM). The authors report an overall response rate of 96%, which is higher than expected, but that translated into a prolonged time to disease progression of 78% at 37 months, especially in patients exposed to lenalidomide for ≥ 3 years. The authors believe the results of the current study confirm that treatment with lenalidomide in combination with dexamethasone is feasible in the long-term treatment of patients with RRMM. The safety profile of long-term exposure to lenalidomide appears to be manageable, with a significant benefit in terms of time to disease progression noted in these patients.

    12. Melanoma
      You have free access to this content
      Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience (pages 3687–3695)

      Jason J. Luke, Margaret K. Callahan, Michael A. Postow, Emanuela Romano, Nikhil Ramaiya, Mark Bluth, Anita Giobbie-Hurder, Donald P. Lawrence, Nageatte Ibrahim, Patrick A. Ott, Keith T. Flaherty, Ryan J. Sullivan, James J. Harding, Sandra D'Angelo, Mark Dickson, Gary K. Schwartz, Paul B. Chapman, Jedd D. Wolchok, F. Stephen Hodi and Richard D. Carvajal

      Version of Record online: 2 AUG 2013 | DOI: 10.1002/cncr.28282

      • image
      • image
      • image

      Ipilimumab can induce clinical responses and durable stable disease, with manageable toxicity, in metastatic uveal melanoma. Eastern Cooperative Oncology Group performance status and pretreatment low-density lipoprotein levels correlate with improved survival in multivariate analysis, and the week-7 absolute lymphocyte count may represent a biomarker of treatment efficacy.

    13. Soft Tissue and Bone Sarcoma
      You have free access to this content
      CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: An independent, multicenter validation study (pages 3696–3702)

      Chiara Colombo, Rosalba Miceli, Alexander J. Lazar, Federica Perrone, Raphael E. Pollock, Axel Le Cesne, Henk H. Hartgrink, Anne-Marie Cleton-Jansen, Julien Domont, Judith V. M. G. Bovée, Sylvie Bonvalot, Dina Lev and Alessandro Gronchi

      Version of Record online: 31 JUL 2013 | DOI: 10.1002/cncr.28271

      • image

      Primary and completely resected desmoid tumors with the CTNNB1 S45F mutation exhibit a greater tendency for local recurrence. With the increasing implementation of a “watchful-waiting” policy as part of desmoid tumor management, it will be important to determine whether mutation type predicts the course of such untreated patients to potentially tailor their treatment.

    14. Discipline

      Bioethics and Legal Oncology
      You have free access to this content
      Pharmacogenetic testing in the face of unclear clinical efficacy: Lessons from cytochrome P450 2D6 for tamoxifen (pages 3703–3709)

      Jeffrey Peppercorn, Erika Hamilton, Paul Kelly Marcom, Laura Beskow and Gary H. Lyman

      Version of Record online: 24 JUL 2013 | DOI: 10.1002/cncr.28263

      • image
      • image
      • image

      Prior to definitive evidence, a minority of oncologists reported using the cytochrome P450 2D6 (CYP2D6) test routinely, and many indicated willingness to change management of patients based on test results. There is a clear need to educate clinicians and the public regarding the uncertain benefits of commercially available genetic tests in clinical practice when evidence from ongoing trials is still emerging.

    15. Outcomes Research
      You have free access to this content
      Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? (pages 3710–3717)

      Erin E. Kent, Laura P. Forsythe, K. Robin Yabroff, Kathryn E. Weaver, Janet S. de Moor, Juan L. Rodriguez and Julia H. Rowland

      Version of Record online: 31 JUL 2013 | DOI: 10.1002/cncr.28262

      • image

      Approximately one-third of individuals with a history of cancer report cancer-related financial problems. Financial problems are disproportionately more common in survivors who are younger, members of a minority group, and report a higher treatment burden history. They are also associated with delaying or forgoing health care because of cost.

    16. Pediatric Oncology
      You have free access to this content
      Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group (pages 3718–3726)

      Larry L. Wang, Rie Suganuma, Naohiko Ikegaki, Xao Tang, Arlene Naranjo, Patrick McGrady, Wendy B. London, Michael D. Hogarty, Julie M. Gastier-Foster, A. Thomas Look, Julie R. Park, John M. Maris, Susan L. Cohn, Robert C. Seeger and Hiroyuki Shimada

      Version of Record online: 30 JUL 2013 | DOI: 10.1002/cncr.28251

      • image
      • image
      • image
      • image
      • image

      Neuroblastoma, undifferentiated subtype, which is the histologically defined entity composed of neuroblasts often having prominent nucleoli, is frequently associated with poor prognostic factors. In this subtype, MYC protein expression could indicate more aggressive clinical behavior than MYCN amplification and subsequent MYCN protein expression.

    17. You have free access to this content
      Sociooccupational and physical outcomes more than 20 years after the diagnosis of osteosarcoma in children and adolescents: Limb salvage versus amputation (pages 3727–3736)

      Giulia Ottaviani, Rhonda S. Robert, Winston W. Huh, Shana Palla and Norman Jaffe

      Version of Record online: 31 JUL 2013 | DOI: 10.1002/cncr.28277

      • image
      • image
      • image
      • image
      • image

      Individuals surviving osteosarcoma for over 20 years described themselves as healthy physically, occupationally, and socially. Despite a slightly more favorable outcome for limb salvaged osteosarcoma survivors, and despite the many challenges that osteosarcoma survivors face, overall they have adjusted well to their physical limitations. Overall, they describe similar health and lifestyle outcomes.

  6. Correspondence

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION